Response Genetics, Inc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGDXQ research report →
Companywww.responsegenetics.com
Response Genetics, Inc. , a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples.
- CEO
- Thomas Bologna
- IPO
- 2007
- Employees
- 96
- HQ
- Los Angeles, CA, US
Price Chart
Valuation
- Market Cap
- $3.87K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 21.85%
- Op Margin
- -118.50%
- Net Margin
- -111.88%
- ROE
- -126.76%
- ROIC
- -49.89%
Growth & Income
- Revenue
- $18.04M · 7.89%
- Net Income
- $-20,184,000 · -49.11%
- EPS
- $-0.52 · -48.57%
- Op Income
- $-21,377,000
- FCF YoY
- -2.36%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 4.94
- Avg Volume
- 42.22K
Get TickerSpark's AI analysis on RGDXQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RGDXQ Coverage
We haven't published any research on RGDXQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGDXQ Report →